Nucl Med Mol Imaging.  2019 Jun;53(3):164-166. 10.1007/s13139-019-00578-x.

Perspectives in Radiomics for Personalized Medicine and Theranostics

• Ha S

• KMID: 2450005
• DOI: http://doi.org/10.1007/s13139-019-00578-x

Abstract

Radiomics handles imaging biomarker from high-throughput feature extraction through complex pattern recognition that is difficult for human to process. Recent medical paradigms are rapidly changing to personalized medicine, including molecular targeted therapy, immunotherapy, and theranostics, and the importance of biomarkers for these is growing day by day. Even though biopsy continues to gold standard for tumor assessment in personalized medicine, imaging is expected to complement biopsy because it allows whole tumor evaluation, whole body evaluation, and non-invasive and repetitive evaluation. Radiomics is known as a useful method to get imaging biomarkers related to intratumor heterogeneity in molecular targeted therapy as well as one-size-fits-all therapy. It is also expected to be useful in new paradigms such as immunotherapy and somatostatin receptor (SSTR) or prostate-specific membrane antigen (PSMA)-targeted theranostics. Radiomics research should move to multimodality (CT, MR, PET, etc.), multicenter, and prospective studies from current single modality, single institution, and retrospective studies. Image-quality harmonization, intertumor heterogeneity, and integrative analysis of information from different scales are thought to be important keywords in future radiomics research. It is clear that radiomics will play an important role in personalized medicine.

Keyword

Radiomics; Personalized medicine; Theranostics; Oncology; PET

MeSH Terms

Biomarkers
Biopsy
Complement System Proteins
Humans
Immunotherapy
Membranes
Methods
Molecular Targeted Therapy
Population Characteristics
Precision Medicine*
Prospective Studies
Receptors, Somatostatin
Retrospective Studies
Theranostic Nanomedicine*
Weights and Measures
Biomarkers
Complement System Proteins
Receptors, Somatostatin